Wall Street Analysts Update Ratings and Price Targets for uniQure N.V.
Several major financial institutions updated their ratings and price targets for uniQure N.V. on November 6, 2026.
Stocks · News reference
uniQure Announces FDA Acceptance and Priority Review of BLA for Huntington's Disease Gene Therapy
The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ifezuntirgene inilparvovec, uniQure's investigational gene therapy for Huntington's disease.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
uniQure Reports Third-Quarter 2026 Financial Results
uniQure N.V. announced its financial results for the third quarter of 2026, reporting revenue of $5.2 million and a net loss of $61.2 million.
8-K filing — uniQure N.V. (QURE)
Filed: 2026-11-04 AccNo: 0001104659-26-122362 Size: 305 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
uniQure to Report Third Quarter 2026 Financial Results on November 4, 2026
uniQure N.V. has scheduled the release of its third quarter 2026 financial results for the morning of Wednesday, November 4, 2026, followed by a conference call.
Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48